Autologous osteoblastic cell therapy - Bone Therapeutics

Drug Profile

Autologous osteoblastic cell therapy - Bone Therapeutics

Alternative Names: Autologous-osteoblastic-cells-Bone-Therapeutics; Autologous-pre-osteoblast-cell-therapy-Bone-Therapeutics; Autologous-pre-osteoblastic-cell-therapy-Bone-Therapeutics; Autologous-preosteoblastic-cells-Bone-Therapeutics; PREOB; PREOB cells

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bone Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Femur head necrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Femur head necrosis
  • Phase II/III Non-union fracture
  • Phase II Osteoporosis

Most Recent Events

  • 20 Oct 2017 Bone Therapeutics terminates a phase II/III trial in Non-union fracture in Belgium and Netherlands to focus resources in the allogeneic platform and provide optimal value for patients (Intraosseous) (NCT01756326)
  • 22 Sep 2017 Autologous osteoblastic cell therapy licensed to Asahi Kasei in Japan
  • 16 Sep 2016 Efficacy data from a clinical trial in Femur head necrosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research-2016 (ASBMR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top